Medical Microinstruments (MMI), a robotics solutions developer for microsurgery, has joined forces with Italian medical technology production and distribution company ab medica to expand commercialisation of its Symani Surgical System across the globe.
The partnership is expected to enhance MMI’s visibility in Italy and increase access to microsurgical robotic technology for providers and patients.
The Symani Surgical System is a robotic technology designed specifically for microsurgery and supermicrosurgery.
It enables surgeons to replicate the natural movements of the human hand at a microscopic scale and can expand treatment options for patients requiring soft tissue open surgical procedures such as lymphatic surgery, free flap reconstructions and trauma reconstructions.
The system helps restore the quality of life for more patients, empower surgeons to push the boundaries of complex procedures for delicate anatomy and allow hospitals to expand their open surgical programmes.
ab medica will leverage its expertise and resources to support the distribution of MMI’s Symani Surgical System in Italy.
With a focus on providing training, clinical support and technical services, the company ensures that physicians and staff have the necessary resources to optimise the capabilities of medical technology at the point of care.
ab medica business director Filippo Pacinotti said: “Working with MMI will significantly strengthen our portfolio with a robotic technology for open surgery at the micro level for precision reconstruction of small blood vessels, nerves and lymphatics using the world’s smallest wristed surgical instruments.”
MMI Europe Middle East and Africa sales vice-president Nicola Matz said: “ab medica has been on the leading edge of surgical robotics technology since the earliest days of the technology, and they are a highly trusted resource for innovators and healthcare providers.
“Our partnership marks a significant step toward expanding the footprint of the Symani Surgical System and providing patients, such as those with breast cancer-related lymphedema or head and neck cancer, with more options for receiving complex care.”
